Clinical TrialJul 15, 2026, 08:37 AM
Kairos Pharma ENV-105 Phase 1 Trial Shows Clean Safety Profile
AI Summary
Kairos Pharma, Ltd. announced compelling interim safety data from its ongoing Phase 1 clinical trial for ENV-105 (Carotuximab) in combination with osimertinib for advanced EGFR-mutated non-small cell lung cancer. The company reported a clean safety profile with zero Grade 3 or higher toxicities associated with ENV-105 across 13 treated patients. This data supports the continued progression of ENV-105, which aims to resensitize patients to osimertinib and address drug resistance in a market valued at approximately $10 billion.
Key Highlights
- Kairos Pharma reported interim safety data from its Phase 1 clinical trial for ENV-105 (Carotuximab).
- The trial evaluates ENV-105 in combination with osimertinib for advanced EGFR-mutated non-small cell lung cancer.
- Zero Grade 3+ toxicities associated with ENV-105 were observed in 13 treated patients.
- ENV-105 aims to resensitize patients to osimertinib, addressing drug resistance in NSCLC.
- The EGFR-NSCLC market is valued at approximately $10 billion, projected to exceed $13 billion by 2030.
- ENV-105 has an ongoing Phase 2 trial for castrate-resistant prostate cancer, showing median PFS over 13 months.
Price Impact
More from KAPA